Business goals

We will receive biospecimens of disease groups donated from all departments (all diseases, needs).
In addition to biopsy tissues and blood, urine, and body fluids, a systematic collection system for fresh-frozen tissues from surgical specimens, which are expected to be the most useful for clinical research and medical development, will be devised.
Collecting biospecimens of healthy people from the Preemptive Medicine and Lifestyle Related Disease Research Center.
We will collect and manage the following types of human biological samples over time:

In the future, we will construct a multi-institutional coordination system including affiliated hospitals.

We will collect medical information on various diseases, such as carcinoma and inflammation, the clinical stage, treatment content, clinical course, and laboratory data over time.
Ensure and implement adequate security for the management of personal information and data.
Establish a system that is linked to electronic medical records to minimize the burden of collection and increase the convenience of using information (after oncology).
Integrative analysis of large amounts of bioinformation, including exhaustive genomic analysis, and omics, over time.
In the future, we will link control information on the quality of samples (e.g., temperature).

In order to control the quality of collected samples, we will confirm the quality of samples to be stored at the time of acceptance and maintain the quality during storage. The storage period of biological samples shall be separately determined according to the contents of the samples, such as quality, results of storage use, and scarcity, in accordance with the International Standards, and the high grade shall be maintained.
We will determine storage control procedures according to the SPREC (Standard PRE analytical Code adopted by IBBL (Integrated BioBank of Luxembourg). We will also participate annually in the international quality control implemented by IBBL.
Using instruments and methods that ensure uniform quality which do not depend on individual differences in operations, such as automated DNA extractors. (Introduced in April 2020) In addition, we will develop biological sample archives, deep freezers, and an IT infrastructure to manage these.
We will contribute to business support with collected samples to form a foundation for drug discovery and medical device development by creating organoids based on high-quality clinical bio-resources through close collaboration with KBBM.

We will develop a system to provide high-quality bio-resources that meet the needs of academia and companies. Specifically, a system will be constructed to seamlessly connect clinical departments that fulfil the needs and systems, such as collection, separation, and storage of necessary bio-resources.
To develop a database of archived bio-resources, and develop a system that makes it easy to access bio-resources to meet the needs. The database will incorporate clinical information that includes not only disease names but also treatment histories and clinical outcomes.
We will also promote construction of a library of processed specimens (organoids) from patients.

In order to avoid hampering the progress of research, we will establish review and supply systems that facilitate the rapid utilization of clinical bio-resources.
Ensuring the priorities of clinical departments that have contributed to the collection of bio-resources and ensuring equality in the use of such resources.
We will permit the use of clinical bio-resources only in studies approved by the Ethics Committee.
Since clinical bio-resources are limited, we will establish a system for review, including the social value, mainly in the biospecimen utilization and management departments.
In cooperation with other departments (engineering, pharmacy, agriculture, science, life sciences, informatics research departments, wildlife research centers, etc.) within academia, the convenience of related researchers and collaborative research, etc., will be improved.
We will formulate networks with domestic and foreign biobanks and repository facilities to improve the convenience of joint research.
We will use KBBM to speed up contracts with companies.

Nurses and medical professionals who provide informed consent for sample collection
Clinical laboratory technicians who are familiar with handling specimens for genome-omics analysis (capable of quality control required by the Genome Task Force), and experts with necessary knowledge, such as on genetics, biochemistry, and molecular biology (equivalent to a gene analysis science certifier), etc.
Human resources familiar with medical information management and processing, such as building and operating a base for collecting information and managing samples
Personnel with adequate knowledge of storage equipment and technologies, such as low-temperature-storage technology for samples
Biomedical informatics that aim to promote an innovative approach based on big data linked to clinical data and comprehensive bioinformation over time.

Business mission